Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Fetscher

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up reportS Fetscher, W Brugger, R Engelhardt, et al.
Seminars in Oncology|April 16, 1998
Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancerW Brugger, S Fetscher, J Hasse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Bone Marrow Transplantation|August 1, 1996
Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimenC F Waller, H Bertz, M K Wenger, et al.
Cancer Genetics and Cytogenetics|March 28, 2003
Cytogenetic and molecular characterization of simultaneous chronic and acute myelocytic leukemiaL Harder, S Gesk, J I Martin-Subero, et al.
Aktuelle Radiologie|December 31, 1997
[Guidelines for standardized diagnosis, therapy and after-care of thyroid cancer]R Engelhardt, E H Farthmann, N Freudenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsC Röllig, M Kramer, M Gabrecht, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 107 patients with non-small-cell lung cancer: a mature follow-up reportS Fetscher, W Brugger, R Engelhardt, et al.
Seminars in Oncology|April 16, 1998
Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancerW Brugger, S Fetscher, J Hasse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancerS Fetscher, W Brugger, R Engelhardt, et al.
Bone Marrow Transplantation|August 1, 1996
Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimenC F Waller, H Bertz, M K Wenger, et al.
Cancer Genetics and Cytogenetics|March 28, 2003
Cytogenetic and molecular characterization of simultaneous chronic and acute myelocytic leukemiaL Harder, S Gesk, J I Martin-Subero, et al.
Aktuelle Radiologie|December 31, 1997
[Guidelines for standardized diagnosis, therapy and after-care of thyroid cancer]R Engelhardt, E H Farthmann, N Freudenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patientsC Röllig, M Kramer, M Gabrecht, et al.
Pageof 4